Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -10 of 19 Show results per page	View Search Criteria \| Help With Results


1.		Vitamin D/Calcium Polyp Prevention Study

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Prevention				Closed				45 to 75				NCI, Other				5 R01 CA098286-03 NCT00153816

Last Modified: 3/1/1998


2.		Phase III Randomized, Double-Blind Study of Nasal Spray Calcitonin vs Placebo to Prevent Osteoporosis in Breast Cancer Patients with Chemotherapy-Induced Ovarian Failure (Summary Last Modified 03/98)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care				Closed				premenopausal				Other				DFCI-92044 NCI-V96-0801

Last Modified: 10/20/2007 First Published: 7/1/1999


3.		Phase III Randomized Study of Zoledronate in Patients With Bone Metastases Secondary to Prostate Cancer (Summary Last Modified 12/1999)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				NOVARTIS-4244603039

Last Modified: 7/14/2008 First Published: 8/1/2001


4.		Phase III Randomized Study of Zoledronate, Calcium, and Cholecalciferol (Vitamin D) to Prevent Bone Loss in Women With Breast Cancer Receiving Adjuvant Chemotherapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care, Treatment				Closed				40 and over				NCI				CALGB-79809 NCI-P01-0184, CALGB-79809, NCT00022087

Last Modified: 1/8/2007 First Published: 8/1/2002


5.		Phase III Randomized Study of Calcium and Cholecalciferol With or Without Conjugated Estrogens and With or Without Risedronate for the Prevention of Osteoporosis in Patients With Prostate Cancer Receiving Androgen-Ablation Therapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care				Closed				18 and over				NCI				NCCTG-N01C8 NCI-P02-0229, N01C8, NCT00043069


6.		Phase III Hormone Therapy with FXM Plus Calcium Carbonate/Vitamin D and Calcitonin for Recurrent Breast Carcinoma with Osseous Metastases

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care, Treatment				Closed				postmenopausal								CBCG-4400

Last Modified: 11/27/2006 First Published: 1/26/2003


7.		Phase III Randomized Study of Risedronate For Prevention of Bone Loss in Premenopausal Women Undergoing Chemotherapy For Primary Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care				Closed				18 and over				NCI				NCCTG-N02C1 N02C1, NCT00054418


8.		A Severity-Adapted Clinical Trial of Diminished Bone Mineral Density in Acute Lymphoblastic Leukemia Survivors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care				Closed				Not specified				Other				BONEII NCT00186901

Last Modified: 6/2/2008 First Published: 7/14/2006


9.		Phase III Companion Study of Bone Mineral Density in Postmenopausal Women With Primary Breast Cancer Treated on Protocol CAN-NCIC-MA27

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Natural history/Epidemiology, Supportive care				Closed				45 and over				NCI				CAN-NCIC-MA27B NCIC-MA.27B, SWOG-NCIC-MA27B, NCCTG-NCIC-MA27B, CAN-NCIC-BONE, NCT00354302, MA27B

Last Modified: 4/1/1988


10.		Phase I/II Study of Therapy with Vit D3 in Patients with Advanced Indolent Lymphomas and Chronic Lymphocytic Leukemia (Summary Last Modified 04/88)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 and over								IOWA-V87-0191 NCI-V87-0191

Select All on One Page


					1 2 Next >

| | | | | | | |

A Service of the National Cancer Institute